Published in Heart on April 29, 2005
Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction. Asian J Androl (2015) 1.50
Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol (2011) 1.00
Effect of wood smoke exposure on vascular function and thrombus formation in healthy fire fighters. Part Fibre Toxicol (2014) 0.79
Mechanism of endothelial cyto-protective and thrombo-resistance effects of sildenafil, vardenafil and tadalafil in male rabbit. Arch Med Sci (2013) 0.78
The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian J Androl (2014) 0.77
Autonomic cerebral vascular response to sildenafil in diabetic patient. Diabetol Metab Syndr (2012) 0.77
Fire Simulation and Cardiovascular Health in Firefighters. Circulation (2017) 0.75
Potentiation of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans. Eur J Appl Physiol (2016) 0.75
Endothelial dysfunction, erectile dysfunction and phosphodiesterase 5 inhibitors. An update of the current data and future perspectives. Drug Target Insights (2007) 0.75
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 5.87
Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation (2000) 5.53
Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation (1993) 4.53
Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet (1993) 3.03
Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest (1990) 2.69
Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension (1995) 2.54
Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb (1994) 2.35
Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol (1999) 2.25
Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation (2003) 2.22
Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation (1996) 1.98
Effects of sildenafil citrate on human hemodynamics. Am J Cardiol (1999) 1.86
Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med (2000) 1.79
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation (1999) 1.79
Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase [corrected]. Circulation (2003) 1.45
The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol (2002) 1.41
Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol (2000) 1.40
Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res (1999) 1.36
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation (2001) 1.32
Endothelial function and nitric oxide: clinical relevance. Heart (2001) 1.32
Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation (2000) 1.28
Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension (1998) 1.20
Effect of NG-monomethyl-L-arginine on kinin-induced vasodilation in the human forearm. Br J Clin Pharmacol (1994) 1.10
Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension (1999) 1.07
Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol (2001) 1.03
Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol (1993) 1.02
An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost (1997) 1.00
Prostaglandins are involved in acetylcholine- and 5-hydroxytryptamine-induced, nitric oxide-mediated vasodilatation in human forearm. J Cardiovasc Pharmacol (2002) 0.99
Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol (2000) 0.98
PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension (2003) 0.96
Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. J Am Coll Cardiol (1998) 0.96
Acetylcholine-mediated vasodilation in the forearm circulation of patients with heart failure: indirect evidence for the role of endothelium-derived hyperpolarizing factor. Am J Cardiol (2001) 0.92
Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation (2000) 0.91
Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. Br J Clin Pharmacol (2004) 0.86
Smoking impairs bradykinin-stimulated t-PA release. Hypertension (2002) 0.86
The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res (1998) 0.81
Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo. Heart (2002) 0.78
Potentiation of thrombolytic therapy by enzyme combinations and with aspirin or pentoxifylline. J Med (1994) 0.77
The effect of pentoxifylline (Trental) and two analogues, BL 194 and HWA 448, on the release of plasminogen activators and von Willebrand factor in rats. J Cardiovasc Pharmacol (1991) 0.77
Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol (1990) 6.73
Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol (1990) 5.20
Guidelines for the management of hemophilia. Haemophilia (2012) 5.16
Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet (1998) 5.15
Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. Proc Natl Acad Sci U S A (1992) 3.58
The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol (2000) 3.43
Infection with hepatitis G virus among recipients of plasma products. Lancet (1996) 3.25
Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med (2001) 2.68
Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations. J Virol (1990) 2.68
Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost (1998) 2.20
The end of the heparin pump? Low molecular weight heparin has many advantages over unfractionated heparin. BMJ (1998) 2.13
Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet (1985) 2.08
Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet (1990) 2.01
New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation. Lancet (1997) 1.94
Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. AIDS (1991) 1.93
New deal for old hearts. BMJ (1991) 1.90
Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. Eur Heart J (2001) 1.87
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation (1999) 1.79
A 'same day' direct-access chest pain clinic: improved management and reduced hospitalization. QJM (1998) 1.77
Interleukin 6 and haemostasis. Br J Haematol (2001) 1.75
Acquired haemophilia and its management. Br J Haematol (1995) 1.69
Cardiovascular effects of particulate air pollution exposure: time course and underlying mechanisms. J Intern Med (2012) 1.68
Treatment for haemophilia by postcode. BMJ (1997) 1.67
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 1.61
Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet (1991) 1.58
Secondhand smoke exposure and survival following acute coronary syndrome: prospective cohort study of 1261 consecutive admissions among never-smokers. Heart (2009) 1.57
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur Heart J (2013) 1.55
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart (2006) 1.55
Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention. Heart (2009) 1.54
Aortic valve calcification on computed tomography predicts the severity of aortic stenosis. Clin Radiol (2003) 1.52
Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations. Eur Heart J (2002) 1.52
Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood (1993) 1.46
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet (2002) 1.46
The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost (1997) 1.45
Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms. J Vasc Surg (1999) 1.44
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res (2000) 1.43
HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet (1988) 1.41
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation (1999) 1.40
Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells--the importance of consensus on the use of correction factors for haemoconcentration. Thromb Haemost (1993) 1.40
Management of acquired von Willebrand's syndrome in a patient requiring major surgery. Haemophilia (2005) 1.40
Hyperinsulinaemia in ischaemic heart disease: the importance of myocardial infarction and left ventricular function. Q J Med (1994) 1.39
Confirmation of non-infection in persistently HIV-seronegative recipients of contaminated factor VIII. Lancet (1990) 1.39
The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) (1998) 1.38
Heart muscle disease related to HIV infection: prognostic implications. BMJ (1994) 1.37
Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation (2001) 1.32
The release of a human platelet specific protein measured by a radioimmunoassay. Thromb Res (1975) 1.31
TT virus--part of the normal human flora? J Infect Dis (1999) 1.29
Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation (2010) 1.28
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J (1999) 1.28
HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohort. Br Med J (Clin Res Ed) (1988) 1.27
Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. Clin Sci (Lond) (1997) 1.27
Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart (2005) 1.26
Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis (1994) 1.23
Thyroid disease and the heart. Heart (2000) 1.18
Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax (2007) 1.17
Peripheral endothelial dysfunction in normal pressure glaucoma. Invest Ophthalmol Vis Sci (1999) 1.16
A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine. J Auton Pharmacol (1983) 1.15
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology (2000) 1.14
A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Health Technol Assess (2009) 1.13
Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost (2001) 1.12
A comparison of symptoms and intra-arterial ambulatory blood pressure during long term dual chamber atrioventricular synchronous (DDD) and ventricular demand (VVI) pacing. Br Heart J (1987) 1.11
Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10
Studies on liberation of beta-thromboglobulin from human platelets in vitro. Br J Haematol (1976) 1.10
Prevention of cardiac complications of non-cardiac surgery: stenosis and thrombosis. Br J Anaesth (2004) 1.09
Discrimination of hepatitis G virus/GBV-C geographical variants by analysis of the 5' non-coding region. J Gen Virol (1997) 1.09
Continuous positive airway pressure improves vascular function in obstructive sleep apnoea/hypopnoea syndrome: a randomised controlled trial. Thorax (2008) 1.08
A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection. Eur Heart J (1995) 1.07
Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.07
Audit of oral anticoagulant treatment. The BCSH Haemostasis and Thrombosis Task Force of the British Society for Haematology. J Clin Pathol (1993) 1.06
Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis (2004) 1.05
Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation (2004) 1.05
Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res (1998) 1.04
Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut (2003) 1.04
EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res (2011) 1.02
Dietary salt and hypertension: treatment and prevention. Br Med J (Clin Res Ed) (1985) 1.02
Myocardial dysfunction in patients infected with HIV: prevalence and risk factors. Br Heart J (1992) 1.02
Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates. Br J Haematol (1992) 1.02
Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology (2001) 1.01
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol (1997) 1.01
A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. Thromb Haemost (1984) 1.01
An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost (1997) 1.00
Cardiac autoimmunity in HIV related heart muscle disease. Heart (1998) 1.00
Three approaches to the radioimmunoassay of human beta-thromboglobulin. Br J Haematol (1976) 0.99
Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart (2006) 0.99
Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort. BMJ (1990) 0.99